EGFR and non-small cell lung carcinoma: In a study conducted by Ochiai and colleagues, the mutational status of EGFR was proposed to influence the recurrence pattern in locally advanced NSCLC post-definitive chemoradiotherapy, with a higher prevalence of distant recurrence among tumors with EGFR mutations compared to EGFR wild-type tumors, which experienced higher rates of local-regional failures (26).